Antroquinonol® is an oral new drug which exhibits a broad spectrum of activities against malignancies in-vivo and in-vitro, and offers a better solution than the single-action compounds the industry developed so far. Antroquinonol’s multiple, simultaneous, and synergistic actions enable positive outcomes. GoldenBiotech has completed the Phase 2 multi-national COVID-19 trial in the US, Peru and Argentina. The trial has been unblinded clinical results in Jan. 2022. Welcome all possible cooperation